Literature DB >> 19489916

Identification of an immunodominant region of Fel d 1 and characterization of constituent epitopes.

E A L Bateman1, M R Ardern-Jones, G S Ogg.   

Abstract

BACKGROUND: Characterization of T cell epitopes restricted by common HLA alleles is a powerful tool in the understanding of the immune responses to allergens and for the identification of potential peptides for future peptide immunotherapy (PIT). One important requirement is the identification and use of peptides that will bind to HLA molecules covering a large proportion of the population.
OBJECTIVE: To identify commonly recognized CD4(+) T cell epitopes in Fel d 1, restricted through frequently expressed HLA molecules for potential future use in PIT.
METHODS: HLA matched antigen presenting cells, HLA blocking antibodies, and peptide truncations were used in ELISpot assays to establish HLA-restricted T cell epitopes. Cytokine responses were measured by ex vivo and cultured IFN-gamma, IL-4, and IL-10 ELISpots.
RESULTS: Responses to an immunodominant region of chain 2 were identified in the majority of atopic individuals and epitopes restricted by HLA-DQB1(*)06 and -DPB1(*)0401 were characterized in detail. Significantly higher ex vivo IL-4 and lower IFN-gamma responses were observed to both epitopes in individuals with atopic dermatitis (AD) compared with those without disease. IL-10 responses were significantly lower in those with AD in the individuals with HLA-DPB1(*)0401.
CONCLUSIONS: We have identified an immunodominant region of Fel d 1 which is frequently recognized by CD4(+) T cells from atopic individuals and contains epitopes that are restricted by very common HLA alleles.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19489916     DOI: 10.1111/j.1365-2222.2008.03098.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  9 in total

1.  Identification and validation of shrimp-tropomyosin specific CD4 T cell epitopes.

Authors:  Eugene V Ravkov; Igor Y Pavlov; Thomas B Martins; Gerald J Gleich; Lori A Wagner; Harry R Hill; Julio C Delgado
Journal:  Hum Immunol       Date:  2013-08-28       Impact factor: 2.850

Review 2.  Allergic sensitization and the environment: latest update.

Authors:  Young Yoo; Matthew S Perzanowski
Journal:  Curr Allergy Asthma Rep       Date:  2014-10       Impact factor: 4.806

3.  Penaeus monodon tropomyosin induces CD4 T-cell proliferation in shrimp-allergic patients.

Authors:  Shuping Wang; Julio C Delgado; Eugene Ravkov; David D Eckels; Ann Georgelas; Igor Y Pavlov; Matthew Cusick; Kate Sebastian; Gerald J Gleich; Lori A Wagner
Journal:  Hum Immunol       Date:  2011-12-28       Impact factor: 2.850

4.  Direct ex vivo analysis of allergen-specific CD4+ T cells.

Authors:  William W Kwok; Michelle Roti; Jonathan H Delong; Venus Tan; Erik Wambre; Eddie A James; David Robinson
Journal:  J Allergy Clin Immunol       Date:  2010-06       Impact factor: 10.793

Review 5.  Mechanisms of tolerance induction in allergic disease: integrating current and emerging concepts.

Authors:  J Wisniewski; R Agrawal; J A Woodfolk
Journal:  Clin Exp Allergy       Date:  2013-02       Impact factor: 5.018

Review 6.  Allergen-Specific CD4(+) T Cells in Human Asthma.

Authors:  Morris F Ling; Andrew D Luster
Journal:  Ann Am Thorac Soc       Date:  2016-03

Review 7.  Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy.

Authors:  S R Prickett; J M Rolland; R E O'Hehir
Journal:  Clin Exp Allergy       Date:  2015-06       Impact factor: 5.018

8.  Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic.

Authors:  S R Prickett; A L Voskamp; T Phan; A Dacumos-Hill; S I Mannering; J M Rolland; R E O'Hehir
Journal:  Clin Exp Allergy       Date:  2013-06       Impact factor: 5.018

Review 9.  T Cell Epitope Peptide Therapy for Allergic Diseases.

Authors:  Robyn E O'Hehir; Sara R Prickett; Jennifer M Rolland
Journal:  Curr Allergy Asthma Rep       Date:  2016-02       Impact factor: 4.806

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.